DEVELOPMENT OF THE AFFINE MOLECULE TO CIS PROTEIN BY METHODS OF STRUCTUREBASED DRUG DESIGN

3

System of recognition of objects in video flow on the basis of virtualization technologies and cloud computing

Облачные технологии – это перспективный и широко применяемый способ обработки и хранения данных. Использование технологий виртуализации позволяет повысить отказоустойчивость предоставляемых сервисов, уменьшить время доставки кода и улучшить утилизацию вычислительных ресурсов. Таким образом возникает потребность использования облачных технологий для решения различных задач. Одной из таких задач является обработка видеопотока. В работе предложен способ построения архитектуры облачной платформы для обработки большого количеств потоков в режиме реального времени. Так же рассмотрены инструменты для конфигурации и развертывания системы. Cloud technologies is a promising and widely used way to process and store data. Using virtualization technologies can increase the fault tolerance of the services provided, reduce the time of code delivery and improve the utilization of computing resources. Thus, there is need to use cloud technology to solve various problems. Video stream processing is one of such tasks. A method for building a cloud platform architecture for processing a large number of streams in real time is proposed. The tools for configuring and deploying the system were discussed

Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)

<p>Abstract</p> <p>Background</p> <p>Blood pressure is considered to be a leading example of a valid surrogate endpoint. The aims of this study were to (i) formally evaluate systolic and diastolic blood pressure reduction as a surrogate endpoint for stroke prevention and (ii) determine what blood pressure reduction would predict a stroke benefit.</p> <p>Methods</p> <p>We identified randomised trials of at least six months duration comparing any pharmacologic anti-hypertensive treatment to placebo or no treatment, and reporting baseline blood pressure, on-trial blood pressure, and fatal and non-fatal stroke. Trials with fewer than five strokes in at least one arm were excluded. Errors-in-variables weighted least squares regression modelled the reduction in stroke as a function of systolic blood pressure reduction and diastolic blood pressure reduction respectively. The lower 95% prediction band was used to determine the minimum systolic blood pressure and diastolic blood pressure difference, the surrogate threshold effect (STE), below which there would be no predicted stroke benefit. The STE was used to generate the surrogate threshold effect proportion (STEP), a surrogacy metric, which with the R-squared trial-level association was used to evaluate blood pressure as a surrogate endpoint for stroke using the Biomarker-Surrogacy Evaluation Schema (BSES3).</p> <p>Results</p> <p>In 18 qualifying trials representing all pharmacologic drug classes of antihypertensives, assuming a reliability coefficient of 0.9, the surrogate threshold effect for a stroke benefit was 7.1 mmHg for systolic blood pressure and 2.4 mmHg for diastolic blood pressure. The trial-level association was 0.41 and 0.64 and the STEP was 66% and 78% for systolic and diastolic blood pressure respectively. The STE and STEP were more robust to measurement error in the independent variable than R-squared trial-level associations. Using the BSES3, assuming a reliability coefficient of 0.9, systolic blood pressure was a B + grade and diastolic blood pressure was an A grade surrogate endpoint for stroke prevention. In comparison, using the same stroke data sets, no STEs could be estimated for cardiovascular (CV) mortality or all-cause mortality reduction, although the STE for CV mortality approached 25 mmHg for systolic blood pressure.</p> <p>Conclusions</p> <p>In this report we provide the first surrogate threshold effect (STE) values for systolic and diastolic blood pressure. We suggest the STEs have face and content validity, evidenced by the inclusivity of trial populations, subject populations and pharmacologic intervention populations in their calculation. We propose that the STE and STEP metrics offer another method of evaluating the evidence supporting surrogate endpoints. We demonstrate how surrogacy evaluations are strengthened if formally evaluated within specific-context evaluation frameworks using the Biomarker- Surrogate Evaluation Schema (BSES3), and we discuss the implications of our evaluation of blood pressure on other biomarkers and patient-reported instruments in relation to surrogacy metrics and trial design.</p

DEVELOPMENT OF THE AFFINE MOLECULE TO CIS PROTEIN BY METHODS OF STRUCTUREBASED DRUG DESIGN

3

Aphid (Homoptera: Aphididae) accumulation and distribution near fences designed for cabbage fly (Diptera: Anthomyiidae) exclusion

Aphids accumulate near exclusion fences designed to intercept Delia radicum (L.) movement into fields. Aphid accumulations increase with increasing fence height, but are not affected by fence overhang length. Overall aphid levels are higher in small (4.3 m square) enclosed plots than in unenclosed plots. Enclosing large (38 m square) plots does not alter overall aphid catches, but does alter aphid distribution within enclosures. In large enclosures aphid accumulations are higher at enclosure perimeters than interiors, with the highest accumulations near enclosure corners. This concentric distribution is not observed in unfenced areas, and is not altered by the addition of a trap crop outside an enclosure.Key words: Myzus persicae; Delia radicum; physical contro